Nina Le Bert1, Upkar S Gill2, Michelle Hong1, Kamini Kunasegaran1, Damien Z M Tan1, Raidah Ahmad1, Yang Cheng3, Charles-A Dutertre4, Andreas Heinecke5, Laura Rivino6, Anthony Tan1, Navjyot K Hansi2, Min Zhang7, Sujuan Xi7, Yutian Chong7, Stefan Pflanz8, Evan W Newell3, Patrick T F Kennedy2, Antonio Bertoletti9. 1. Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore. 2. Barts Liver Centre, Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom. 3. Singapore Immunology Network, A∗STAR, Singapore. 4. Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore; Singapore Immunology Network, A∗STAR, Singapore. 5. Division of Science, Yale-NUS College, Singapore. 6. Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore; School of Cellular and Molecular Medicine, University of Bristol, United Kingdom. 7. Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. 8. Gilead Sciences, Inc, Department of Biology, Foster City, California. 9. Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore; Singapore Immunology Network, A∗STAR, Singapore. Electronic address: antonio@duke-nus.edu.sg.
Abstract
BACKGROUND & AIMS: Chronic hepatitis B virus (HBV) infection is characterized by the presence of defective viral envelope proteins (hepatitis B surface antigen [HBsAg]) and the duration of infection-most patients acquire the infection at birth or during the first years of life. We investigated the effects of these factors on patients' lymphocyte and HBV-specific T-cell populations. METHODS: We collected blood samples and clinical data from 243 patients with HBV infection (3-75 years old) in the United Kingdom and China. We measured levels of HBV DNA, HBsAg, hepatitis B e antigen, and alanine aminotransferase; analyzed HBV genotypes; and isolated peripheral blood mononuclear cells (PBMCs). In PBMCs from 48 patients with varying levels of serum HBsAg, we measured 40 markers on nature killer and T cells by mass cytometry. PBMCs from 189 patients with chronic infection and 38 patients with resolved infections were incubated with HBV peptide libraries, and HBV-specific T cells were identified by interferon gamma enzyme-linked immune absorbent spot (ELISpot) assays or flow cytometry. We used multivariate linear regression and performed variable selection using the Akaike information criterion to identify covariates associated with HBV-specific responses of T cells. RESULTS: Although T- and natural killer cell phenotypes and functions did not change with level of serum HBsAg, numbers of HBs-specific T cells correlated with serum levels of HBsAg (r = 0.3367; P < .00001). After we performed the variable selection, the multivariate linear regression model identified patient age as the only factor significantly associated with numbers of HBs-specific T cells (P = .000115). In patients younger than 30 years, HBs-specific T cells constituted 28.26% of the total HBV-specific T cells; this value decreased to 7.14% in patients older than 30 years. CONCLUSIONS: In an analysis of immune cells from patients with chronic HBV infection, we found that the duration of HBsAg exposure, rather than the quantity of HBsAg, was associated with the level of anti-HBV immune response. Although the presence of HBs-specific T cells might not be required for the clearance of HBV infection in all patients, strategies to restore anti-HBV immune responses should be considered in patients younger than 30 years.
BACKGROUND & AIMS: Chronic hepatitis B virus (HBV) infection is characterized by the presence of defective viral envelope proteins (hepatitis B surface antigen [HBsAg]) and the duration of infection-most patients acquire the infection at birth or during the first years of life. We investigated the effects of these factors on patients' lymphocyte and HBV-specific T-cell populations. METHODS: We collected blood samples and clinical data from 243 patients with HBV infection (3-75 years old) in the United Kingdom and China. We measured levels of HBV DNA, HBsAg, hepatitis B e antigen, and alanine aminotransferase; analyzed HBV genotypes; and isolated peripheral blood mononuclear cells (PBMCs). In PBMCs from 48 patients with varying levels of serum HBsAg, we measured 40 markers on nature killer and T cells by mass cytometry. PBMCs from 189 patients with chronic infection and 38 patients with resolved infections were incubated with HBV peptide libraries, and HBV-specific T cells were identified by interferon gamma enzyme-linked immune absorbent spot (ELISpot) assays or flow cytometry. We used multivariate linear regression and performed variable selection using the Akaike information criterion to identify covariates associated with HBV-specific responses of T cells. RESULTS: Although T- and natural killer cell phenotypes and functions did not change with level of serum HBsAg, numbers of HBs-specific T cells correlated with serum levels of HBsAg (r = 0.3367; P < .00001). After we performed the variable selection, the multivariate linear regression model identified patient age as the only factor significantly associated with numbers of HBs-specific T cells (P = .000115). In patients younger than 30 years, HBs-specific T cells constituted 28.26% of the total HBV-specific T cells; this value decreased to 7.14% in patients older than 30 years. CONCLUSIONS: In an analysis of immune cells from patients with chronic HBV infection, we found that the duration of HBsAg exposure, rather than the quantity of HBsAg, was associated with the level of anti-HBV immune response. Although the presence of HBs-specific T cells might not be required for the clearance of HBV infection in all patients, strategies to restore anti-HBV immune responses should be considered in patients younger than 30 years.
Authors: Cassandra L Gorsuch; Paige Nemec; Mei Yu; Simin Xu; Dong Han; Jeff Smith; Janel Lape; Nicholas van Buuren; Ricardo Ramirez; Robert C Muench; Meghan M Holdorf; Becket Feierbach; Greg Falls; Jason Holt; Wendy Shoop; Emma Sevigny; Forrest Karriker; Robert V Brown; Amod Joshi; Tyler Goodwin; Ying K Tam; Paulo J C Lin; Sean C Semple; Neil Leatherbury; William E Delaney Iv; Derek Jantz; Amy Rhoden Smith Journal: Mol Ther Date: 2022-05-16 Impact factor: 12.910
Authors: Andrea Magri; James M Harris; Valentina D'Arienzo; Rosalba Minisini; Frank Jühling; Peter A C Wing; Rachele Rapetti; Monica Leutner; Barbara Testoni; Thomas F Baumert; Fabien Zoulim; Peter Balfe; Mario Pirisi; Jane A McKeating Journal: Viruses Date: 2022-05-17 Impact factor: 5.818
Authors: Kathrin Heim; Benedikt Binder; Dominik Wieland; Nina Hensel; Sian Llewellyn-Lacey; Emma Gostick; David A Price; Florian Emmerich; Hildegard Vingerhoet; Anke R M Kraft; Markus Cornberg; Tobias Boettler; Christoph Neumann-Haefelin; Dietmar Zehn; Bertram Bengsch; Maike Hofmann; Robert Thimme Journal: Gut Date: 2020-10-23 Impact factor: 23.059